Read articles from United States of America

September 24, 2026 by substack.com

Pennsylvania’s teen vaping trend tells a less dramatic story than many policy campaigns suggest. Youth use is falling, yet the political response often remains locked in crisis mode, with restrictions aimed at a problem that may already be moving in the right direction. That matters because outdated alarm can distort priorities and spill over onto adults who smoke. Prevention should follow the data, not preserve a panic after the trend has changed.

September 24, 2026 by substack.com

Knowledge is power in tobacco harm reduction because it gives smokers something more useful than fear. Understanding combustion, nicotine, relative risk and switching can change the choices people believe are available to them. Poor information keeps cigarettes protected by confusion, while clear information helps adults see a route away from the most harmful product. Public health should not be afraid of informed consumers; it should depend on them.

September 23, 2026 by substack.com

Knowledge is power in tobacco harm reduction because it gives smokers something more useful than fear. Understanding combustion, nicotine, relative risk and switching can change the choices people believe are available to them. Poor information keeps cigarettes protected by confusion, while clear information helps adults see a route away from the most harmful product. Public health should not be afraid of informed consumers; it should depend on them.

September 23, 2026 by 2firsts.com

A nicotine substitute entering the market before key human evidence is available should make regulators ask better questions, not reach for easy assumptions. New molecules such as 6-methyl nicotine may sit outside familiar tobacco and nicotine frameworks, but that does not make them automatically safer, riskier or irrelevant. The priority should be transparent testing, pharmacology, exposure data and real-world monitoring before public health claims are made. Innovation can support harm reduction only when the evidence keeps pace with the product.

September 23, 2026 by 2firsts.com

A nicotine substitute entering the market before key human evidence is available should make regulators ask better questions, not reach for easy assumptions. New molecules such as 6-methyl nicotine may sit outside familiar tobacco and nicotine frameworks, but that does not make them automatically safer, riskier or irrelevant. The priority should be transparent testing, pharmacology, exposure data and real-world monitoring before public health claims are made. Innovation can support harm reduction only when the evidence keeps pace with the product.

September 22, 2026 by reason.org

Half a billion dollars to fight a collapsing trend deserves scrutiny. Youth vaping has fallen sharply, yet lawmakers are still treating it as an expanding emergency while adult smoking remains the bigger driver of preventable disease. Resources should follow the scale of harm, not the politics of alarm. Serious nicotine policy would protect young people without using outdated crisis language to justify measures that may also make quitting harder for adults.

September 22, 2026 by thejournal.ie

The phrase “vaping is worse than smoking” does more than misstate the evidence — it changes behaviour. A smoker who believes that message may see little reason to switch, even though cigarettes remain the far more harmful product. Good fact-checking restores the missing hierarchy: vaping is not harmless, but it is not smoking. Clear risk communication can be the difference between staying with combustion and taking a less harmful route away from it.

September 21, 2026 by regulatorwatch.com

Nicotine pouch testing should be driven by science, not suspicion by category. Better data on ingredients, emissions, exposure and product performance can help regulators distinguish between responsible smoke-free products and those that fail basic standards. That matters because credible harm reduction depends on transparency as much as access. The stronger the testing framework, the harder it becomes to dismiss pouches with fear — or to defend products that do not meet the evidence.

September 21, 2026 by desmoinesregister.com

Tobacco control embracing harm reduction would mark a shift from fighting nicotine use in the abstract to reducing the harms that actually kill. FDA vaping policy should recognise that adult smokers need legal, evidence-based alternatives capable of moving them away from combustion. That does not weaken prevention or youth protection; it makes the overall strategy more realistic. Public health progress depends on helping people stop smoking, not on treating every nicotine product as the same threat.

September 18, 2026 by linknky.com

Veterans who smoke need support that recognises habit, stress, trauma and dependence rather than reducing quitting to willpower. Many have tried to stop before, and some may need lower-risk nicotine options that meet them where they are. Harm reduction can create a more realistic path from habit to health by reducing exposure to combustion while keeping people engaged in care. Better cessation support should be practical, respectful and tailored to the lives of those it aims to help.